search
Documents
Aggregate Analysis of Liraglutide Using Biozen dSEC-1
This study demonstrates the effectiveness of Biozen dSEC-1 SEC columns for monitoring Liraglutide aggregation, a critical quality attribute for GLP-1 peptide therapeutics. The hydrophilic stationary phase minimized non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were resolved in a 12-minute run with Rs up to 1.96 and excellent reproducibility (retention time RSD ≤ 0.08%, peak area RSD ≤ 5.4%). High sensitivity enabled detection of aggregates even in stressed samples, confirming Biozen dSEC-1 as a robust solution for Liraglutide aggregation analysis.
Aggregate Analysis of Liraglutide Using Biozen dSEC-1
This study demonstrates the effectiveness of Biozen dSEC-1 SEC columns for monitoring Liraglutide aggregation, a critical quality attribute for GLP-1 peptide therapeutics. The hydrophilic stationary phase minimized non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were resolved in a 12-minute run with Rs up to 1.96 and excellent reproducibility (retention time RSD ≤ 0.08%, peak area RSD ≤ 5.4%). High sensitivity enabled detection of aggregates even in stressed samples, confirming Biozen dSEC-1 as a robust solution for Liraglutide aggregation analysis.
Document Type:
Technical Notes
Target Industries:
Brands:
Separation Modes:
Size Exclusion
Phases:
Aggregate Analysis of Liraglutide Using Biozen dSEC-1
This study demonstrates the effectiveness of Biozen dSEC-1 SEC columns for monitoring Liraglutide aggregation, a critical quality attribute for GLP-1 peptide therapeutics. The hydrophilic stationary phase minimized non-specific interactions, eliminating the need for high organic or acidic mobile phases. Using a 150 mm (1.6 um) column, monomer and two aggregate species were resolved in a 12-minute run with Rs up to 1.96 and excellent reproducibility (retention time RSD ≤ 0.08%, peak area RSD ≤ 5.4%). High sensitivity enabled detection of aggregates even in stressed samples, confirming Biozen dSEC-1 as a robust solution for Liraglutide aggregation analysis.
| Target Industries: | Biopharmaceutical Analysis |
| Techniques: | HPLC, HPLC-SEC |
| Brands: | Biozen LC |
| Separation Modes: | Size Exclusion |
| Phases: | Biozen dSEC-1 |
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.
Phenomenex is a technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers worldwide.